Previous close | 8.10 |
Open | 19.35 |
Bid | 17.40 |
Ask | 24.50 |
Strike | 1,040.00 |
Expiry date | 2024-06-28 |
Day's range | 19.35 - 19.65 |
Contract range | N/A |
Volume | |
Open interest | 14 |
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...